{"success":true,"data":{"pressRelease":{"id":"180624","rtpr_id":"nPn7hHrJSa-20261027","ticker":"CC","exchange":"NYSE","all_tickers":["CC"],"title":"CC Investor Class Action Filed: Chemours Investors Are Alerted to the Upcoming December 7 Deadline in the Securities Fraud Class Action to Recover Losses","author":"PR Newswire","published_at":"2026-10-27T09:46:01.427Z","article_body":"CC Investor Class Action Filed: Chemours Investors Are Alerted to the Upcoming December 7 Deadline in the Securities Fraud Class Action to Recover Losses\nPR Newswire\n\nNEW YORK, Oct. 27, 2026\n\nChemours has been sued for securities fraud after its stock plummeted 18.63%\nbecause Chemours allegedly misrepresented the strength of demand for its\nOpteon products.\n\nNEW YORK, Oct. 27, 2026 /PRNewswire/ -- Leading securities law firm Bleichmar\nFonti & Auld LLP\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4806924-1&h=3338587694&u=https%3A%2F%2Fwww.bfalaw.com%2Fcases%2Fchemours-class-action-lawsuit&a=Bleichmar+Fonti+%26+Auld+LLP)\n announces that a class action lawsuit has been filed against The Chemours\nCompany (NYSE: CC) and certain of the company's senior executives for\nsecurities fraud after a significant stock drop resulting from potential\nviolations of the federal securities laws.\n\nIf you invested in Chemours, you are encouraged to obtain additional\ninformation by\nvisiting: https://www.bfalaw.com/cases/chemours-class-action-lawsuit\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4806924-1&h=4249338325&u=https%3A%2F%2Fwww.bfalaw.com%2Fcases%2Fchemours-class-action-lawsuit&a=https%3A%2F%2Fwww.bfalaw.com%2Fcases%2Fchemours-class-action-lawsuit)\n.\n\nKey Details of the Chemours ($CC) Class Action:\n\n * Lead Plaintiff Deadline: December 7, 2026\n * Alleged Misconduct: Securities fraud alleging Chemours misrepresented the\nstrength of demand for its Opteon products\n * Stock Drop: August 5, 2026 – 18.63% Stock Drop\n * Court: U.S. District Court for the District of Delaware\n * Action: Contact\nBFA Law\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4806924-1&h=4101574533&u=https%3A%2F%2Fwww.bfalaw.com%2Fcases%2Fchemours-class-action-lawsuit&a=BFA+Law)\n\n to discuss your rights\nInvestors have until December 7, 2026 to ask the Court to be appointed to lead\nthe case. The complaint asserts securities fraud claims under Sections 10(b)\nand 20(a) of the Securities Exchange Act of 1934 on behalf of investors in\nChemours securities. The class action is pending in the U.S. District Court\nfor the District of Delaware. It is captioned Darcy v. The Chemours Company,\nNo. 26-cv-1299.\n\nWhy is Chemours Being Sued for Securities Fraud?\n\nChemours offers a range of industrial and specialty chemical products,\nincluding Opteon, a set of refrigeration chemicals with a reduced\nozone-depletion footprint. In late 2020, Congress enacted the U.S. AIM Act,\nwhich directed the EPA to oversee the transition to alternative refrigerants\nthat present a lesser impact to the ozone layer.\n\nAccording to the complaint, Chemours stated that continued adoption of the AIM\nAct drove sustained growth for its Opteon products. Chemours stated that the\n\"sustained double-digit\" Opteon expansion would be \"driven by the continued\nregulatory adoption\" of the AIM Act. What's more, Chemours provided 2026 net\nsales guidance of 3% to 5% growth and 2026 adjusted EBITDA guidance of $800M\n– $900M, driven by \"higher . . . demand\" in its Opteon segment.\n\nAs alleged, Chemours failed to disclose that customers were already\noversupplied with Opteon products because of the AIM Act transition, leading\nto an \"oversupplied channel heading into 2026.\"\n\nWhy did Chemours's Stock Drop?\n\nOn August 4, 2026, Chemours announced Q2 2026 financial results, revealing an\napproximately 1% year-over-year decrease in net sales and cutting 2026\nadjusted EBITDA guidance by about 11% (to $775M – $825M from $800M –\n$900M). Chemours also revealed that customers had \"built additional inventory\"\nof Opteon products the prior year, that aftermarket channels had been filled,\nand that Chemours was selling into an \"oversupplied channel heading into\n2026.\"\n\nOn this news, Chemours's stock dropped $3.34 per share, or 18.63%, from a\nclosing price of $17.93 per share on August 4, 2026, to $14.59 per share on\nAugust 5, 2026.\n\nClick here for more information:\nhttps://www.bfalaw.com/cases/chemours-class-action-lawsuit\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4806924-1&h=4249338325&u=https%3A%2F%2Fwww.bfalaw.com%2Fcases%2Fchemours-class-action-lawsuit&a=https%3A%2F%2Fwww.bfalaw.com%2Fcases%2Fchemours-class-action-lawsuit)\n.\n\nWhat Can You Do?\n\nIf you invested in Chemours, you may have legal options and are encouraged to\nsubmit your information to the firm.\n\nAll representation is on a contingency fee basis; there is no cost to you.\nShareholders are not responsible for any court costs or expenses of\nlitigation. The firm will seek court approval for any potential fees and\nexpenses.\n\nSubmit your information by visiting:\n\nhttps://www.bfalaw.com/cases/chemours-class-action-lawsuit\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4806924-1&h=4249338325&u=https%3A%2F%2Fwww.bfalaw.com%2Fcases%2Fchemours-class-action-lawsuit&a=https%3A%2F%2Fwww.bfalaw.com%2Fcases%2Fchemours-class-action-lawsuit)\n\nWhy Bleichmar Fonti & Auld LLP?\n\nBFA is a leading international law firm representing plaintiffs in securities\nclass actions and shareholder litigation. It has been named a top plaintiff\nlaw firm by Chambers USA, The Legal 500, and ISS SCAS, and its attorneys have\nbeen named \"Elite Trial Lawyers\" by the National Law Journal, \"Litigation\nStars\" by Benchmark Litigation, among the top \"500 Leading Plaintiff\nFinancial Lawyers\" by Lawdragon, \"Titans of the Plaintiffs' Bar\" by Law360,\nand \"SuperLawyers\" by Thomson Reuters.\n\nMost recently, The Legal 500 awarded BFA the most client satisfaction\naccolades of any plaintiff's securities litigation law firm, with clients\nnoting: \"[t]here is no better service provider in the practice area,\" \"[t]he\ninterest of the client is always front and center,\" and \"[t]here isn't a\nbetter firm in this space.\" One testimonial described the firm as \"nimble and\nentrepreneurial,\" with a \"relentless focus on adding value for clients.\"\n\nBFA's notable successes include a recovery of over $900 million in value from\nTesla, Inc.'s Board of Directors, as well as $420 million from Teva\nPharmaceutical Ind. Ltd.\n\nFor more information about BFA and its attorneys, please visit\nhttps://www.bfalaw.com\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4806924-1&h=1556079158&u=https%3A%2F%2Fwww.bfalaw.com%2F&a=https%3A%2F%2Fwww.bfalaw.com)\n.\n\nhttps://www.bfalaw.com/cases/chemours-class-action-lawsuit\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4806924-1&h=4249338325&u=https%3A%2F%2Fwww.bfalaw.com%2Fcases%2Fchemours-class-action-lawsuit&a=https%3A%2F%2Fwww.bfalaw.com%2Fcases%2Fchemours-class-action-lawsuit)\n\nAttorney advertising. Past results do not guarantee future outcomes.\n\nView original content to download\nmultimedia:https://www.prnewswire.com/news-releases/cc-investor-class-action-filed-chemours-investors-are-alerted-to-the-upcoming-december-7-deadline-in-the-securities-fraud-class-action-to-recover-losses-302920161.html\n(https://www.prnewswire.com/news-releases/cc-investor-class-action-filed-chemours-investors-are-alerted-to-the-upcoming-december-7-deadline-in-the-securities-fraud-class-action-to-recover-losses-302920161.html)\n\nSOURCE Bleichmar Fonti & Auld LLP\n\n\n\nAdam McCall, adam@bfalaw.com, 212.789.3619\n\nPhoto: \nhttps://mmx.prnewswire.com/media/MS1804470/Bleichmar-Fonti-Auld-LLP-Logo.jpg?id=OA3040469\n\nCopyright (c) 2026 PR Newswire Association,LLC. All Rights Reserved.","article_body_html":"","raw_payload":{"data":{"id":"nPn7hHrJSa-20261027","title":"CC Investor Class Action Filed: Chemours Investors Are Alerted to the Upcoming December 7 Deadline in the Securities Fraud Class Action to Recover Losses","author":"PR Newswire","ticker":"CC","created":"2026-10-27T09:46:01.427Z","tickers":["CC"],"exchange":"NYSE","article_body":"CC Investor Class Action Filed: Chemours Investors Are Alerted to the Upcoming December 7 Deadline in the Securities Fraud Class Action to Recover Losses\nPR Newswire\n\nNEW YORK, Oct. 27, 2026\n\nChemours has been sued for securities fraud after its stock plummeted 18.63%\nbecause Chemours allegedly misrepresented the strength of demand for its\nOpteon products.\n\nNEW YORK, Oct. 27, 2026 /PRNewswire/ -- Leading securities law firm Bleichmar\nFonti & Auld LLP\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4806924-1&h=3338587694&u=https%3A%2F%2Fwww.bfalaw.com%2Fcases%2Fchemours-class-action-lawsuit&a=Bleichmar+Fonti+%26+Auld+LLP)\n announces that a class action lawsuit has been filed against The Chemours\nCompany (NYSE: CC) and certain of the company's senior executives for\nsecurities fraud after a significant stock drop resulting from potential\nviolations of the federal securities laws.\n\nIf you invested in Chemours, you are encouraged to obtain additional\ninformation by\nvisiting: https://www.bfalaw.com/cases/chemours-class-action-lawsuit\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4806924-1&h=4249338325&u=https%3A%2F%2Fwww.bfalaw.com%2Fcases%2Fchemours-class-action-lawsuit&a=https%3A%2F%2Fwww.bfalaw.com%2Fcases%2Fchemours-class-action-lawsuit)\n.\n\nKey Details of the Chemours ($CC) Class Action:\n\n * Lead Plaintiff Deadline: December 7, 2026\n * Alleged Misconduct: Securities fraud alleging Chemours misrepresented the\nstrength of demand for its Opteon products\n * Stock Drop: August 5, 2026 – 18.63% Stock Drop\n * Court: U.S. District Court for the District of Delaware\n * Action: Contact\nBFA Law\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4806924-1&h=4101574533&u=https%3A%2F%2Fwww.bfalaw.com%2Fcases%2Fchemours-class-action-lawsuit&a=BFA+Law)\n\n to discuss your rights\nInvestors have until December 7, 2026 to ask the Court to be appointed to lead\nthe case. The complaint asserts securities fraud claims under Sections 10(b)\nand 20(a) of the Securities Exchange Act of 1934 on behalf of investors in\nChemours securities. The class action is pending in the U.S. District Court\nfor the District of Delaware. It is captioned Darcy v. The Chemours Company,\nNo. 26-cv-1299.\n\nWhy is Chemours Being Sued for Securities Fraud?\n\nChemours offers a range of industrial and specialty chemical products,\nincluding Opteon, a set of refrigeration chemicals with a reduced\nozone-depletion footprint. In late 2020, Congress enacted the U.S. AIM Act,\nwhich directed the EPA to oversee the transition to alternative refrigerants\nthat present a lesser impact to the ozone layer.\n\nAccording to the complaint, Chemours stated that continued adoption of the AIM\nAct drove sustained growth for its Opteon products. Chemours stated that the\n\"sustained double-digit\" Opteon expansion would be \"driven by the continued\nregulatory adoption\" of the AIM Act. What's more, Chemours provided 2026 net\nsales guidance of 3% to 5% growth and 2026 adjusted EBITDA guidance of $800M\n– $900M, driven by \"higher . . . demand\" in its Opteon segment.\n\nAs alleged, Chemours failed to disclose that customers were already\noversupplied with Opteon products because of the AIM Act transition, leading\nto an \"oversupplied channel heading into 2026.\"\n\nWhy did Chemours's Stock Drop?\n\nOn August 4, 2026, Chemours announced Q2 2026 financial results, revealing an\napproximately 1% year-over-year decrease in net sales and cutting 2026\nadjusted EBITDA guidance by about 11% (to $775M – $825M from $800M –\n$900M). Chemours also revealed that customers had \"built additional inventory\"\nof Opteon products the prior year, that aftermarket channels had been filled,\nand that Chemours was selling into an \"oversupplied channel heading into\n2026.\"\n\nOn this news, Chemours's stock dropped $3.34 per share, or 18.63%, from a\nclosing price of $17.93 per share on August 4, 2026, to $14.59 per share on\nAugust 5, 2026.\n\nClick here for more information:\nhttps://www.bfalaw.com/cases/chemours-class-action-lawsuit\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4806924-1&h=4249338325&u=https%3A%2F%2Fwww.bfalaw.com%2Fcases%2Fchemours-class-action-lawsuit&a=https%3A%2F%2Fwww.bfalaw.com%2Fcases%2Fchemours-class-action-lawsuit)\n.\n\nWhat Can You Do?\n\nIf you invested in Chemours, you may have legal options and are encouraged to\nsubmit your information to the firm.\n\nAll representation is on a contingency fee basis; there is no cost to you.\nShareholders are not responsible for any court costs or expenses of\nlitigation. The firm will seek court approval for any potential fees and\nexpenses.\n\nSubmit your information by visiting:\n\nhttps://www.bfalaw.com/cases/chemours-class-action-lawsuit\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4806924-1&h=4249338325&u=https%3A%2F%2Fwww.bfalaw.com%2Fcases%2Fchemours-class-action-lawsuit&a=https%3A%2F%2Fwww.bfalaw.com%2Fcases%2Fchemours-class-action-lawsuit)\n\nWhy Bleichmar Fonti & Auld LLP?\n\nBFA is a leading international law firm representing plaintiffs in securities\nclass actions and shareholder litigation. It has been named a top plaintiff\nlaw firm by Chambers USA, The Legal 500, and ISS SCAS, and its attorneys have\nbeen named \"Elite Trial Lawyers\" by the National Law Journal, \"Litigation\nStars\" by Benchmark Litigation, among the top \"500 Leading Plaintiff\nFinancial Lawyers\" by Lawdragon, \"Titans of the Plaintiffs' Bar\" by Law360,\nand \"SuperLawyers\" by Thomson Reuters.\n\nMost recently, The Legal 500 awarded BFA the most client satisfaction\naccolades of any plaintiff's securities litigation law firm, with clients\nnoting: \"[t]here is no better service provider in the practice area,\" \"[t]he\ninterest of the client is always front and center,\" and \"[t]here isn't a\nbetter firm in this space.\" One testimonial described the firm as \"nimble and\nentrepreneurial,\" with a \"relentless focus on adding value for clients.\"\n\nBFA's notable successes include a recovery of over $900 million in value from\nTesla, Inc.'s Board of Directors, as well as $420 million from Teva\nPharmaceutical Ind. Ltd.\n\nFor more information about BFA and its attorneys, please visit\nhttps://www.bfalaw.com\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4806924-1&h=1556079158&u=https%3A%2F%2Fwww.bfalaw.com%2F&a=https%3A%2F%2Fwww.bfalaw.com)\n.\n\nhttps://www.bfalaw.com/cases/chemours-class-action-lawsuit\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4806924-1&h=4249338325&u=https%3A%2F%2Fwww.bfalaw.com%2Fcases%2Fchemours-class-action-lawsuit&a=https%3A%2F%2Fwww.bfalaw.com%2Fcases%2Fchemours-class-action-lawsuit)\n\nAttorney advertising. Past results do not guarantee future outcomes.\n\nView original content to download\nmultimedia:https://www.prnewswire.com/news-releases/cc-investor-class-action-filed-chemours-investors-are-alerted-to-the-upcoming-december-7-deadline-in-the-securities-fraud-class-action-to-recover-losses-302920161.html\n(https://www.prnewswire.com/news-releases/cc-investor-class-action-filed-chemours-investors-are-alerted-to-the-upcoming-december-7-deadline-in-the-securities-fraud-class-action-to-recover-losses-302920161.html)\n\nSOURCE Bleichmar Fonti & Auld LLP\n\n\n\nAdam McCall, adam@bfalaw.com, 212.789.3619\n\nPhoto: \nhttps://mmx.prnewswire.com/media/MS1804470/Bleichmar-Fonti-Auld-LLP-Logo.jpg?id=OA3040469\n\nCopyright (c) 2026 PR Newswire Association,LLC. All Rights Reserved."},"type":"article","timestamp":"2026-10-27T09:46:01.476047858Z","server_sent_at_ms":1793094361476},"received_at":"2026-10-27T09:46:01.542Z","source_url":"https://www.prnewswire.com/news-releases/cc-investor-class-action-filed-chemours-investors-are-alerted-to-the-upcoming-december-7-deadline-in-the-securities-fraud-class-action-to-recover-losses-302920161.html"},"analysis":{"id":"168461","press_release_id":"180624","analysis_json":{"industry":{"label":"Chemicals","sector":"Materials"},"redFlags":["securities fraud class action alleging demand misrepresentation for Opteon products","prior 18.63% single-day stock drop following guidance cut","admitted customer channel oversupply / inventory build heading into 2026"],"eventType":"legal_litigation","narrative":"A securities fraud class action has been filed against Chemours (NYSE: CC) in the U.S. District Court for the District of Delaware, alleging the company misrepresented demand for its Opteon refrigerant products ahead of an 18.63% stock drop on August 5, 2026.\n\nThis release is a lead-plaintiff solicitation from plaintiff law firm Bleichmar Fonti & Auld LLP, with an investor deadline of December 7, 2026; no new company disclosure is included.\n\nThe underlying allegations stem from Chemours cutting 2026 adjusted EBITDA guidance roughly 11% to $775M-$825M at Q2 2026 results, after admitting customers had built excess Opteon inventory and the channel was oversupplied heading into 2026.","sentiment":"bearish","agentHooks":{"shouldPost":false,"suggestedAngle":"Plaintiff-firm solicitation following an already-disclosed guidance cut -- suppress posting; the litigation overhang itself is the risk item."},"keyFigures":{"customDimensions":{"stock_drop_date":"August 5, 2026","stock_drop_percent":"18.63%","stock_drop_price_to":14.59,"stock_drop_price_from":17.93,"ebitda_guidance_cut_to":"$775M – $825M","lead_plaintiff_deadline":"December 7, 2026","q2_net_sales_change_yoy":"approximately -1%","ebitda_guidance_cut_from":"$800M – $900M"}},"quotedText":"Chemours failed to disclose that customers were already oversupplied with Opteon products because of the AIM Act transition","namedEntities":{"people":[{"name":"Adam McCall","role":"law firm contact"}],"products":["Opteon"],"companies":[{"name":"The Chemours Company","ticker":"CC","relationship":"target of class action"},{"name":"Bleichmar Fonti & Auld LLP","relationship":"plaintiff law firm"}],"dollarAmounts":[{"amount":"$800M – $900M","context":"original 2026 adjusted EBITDA guidance"},{"amount":"$775M – $825M","context":"cut 2026 adjusted EBITDA guidance"},{"amount":"$3.34 per share","context":"August 5, 2026 stock drop"},{"amount":"$17.93 per share","context":"closing price August 4, 2026"},{"amount":"$14.59 per share","context":"closing price August 5, 2026"}]},"materialImpact":{"score":2,"reasoning":"Plaintiff law-firm solicitation (Bleichmar Fonti & Auld) regarding a securities fraud class action against Chemours. The lawsuit itself confirms an 18.63% stock drop and guidance cut, but this release is firm marketing, not new issuer disclosure; scored 2 given the large stock drop and demand-misrepresentation allegations behind the case."},"tickerRelevance":{"others":[],"primary":"CC"},"globalImportance":20,"audienceRelevance":25,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"mid-cap","eventGravity":"law-firm-solicitation","issuerAuthored":false,"underlyingSeverity":"large stock drop and guidance cut already public"}},"event_type":"legal_litigation","event_type_secondary":null,"sentiment":"bearish","material_impact_score":2,"narrative":"A securities fraud class action has been filed against Chemours (NYSE: CC) in the U.S. District Court for the District of Delaware, alleging the company misrepresented demand for its Opteon refrigerant products ahead of an 18.63% stock drop on August 5, 2026.\n\nThis release is a lead-plaintiff solicitation from plaintiff law firm Bleichmar Fonti & Auld LLP, with an investor deadline of December 7, 2026; no new company disclosure is included.\n\nThe underlying allegations stem from Chemours cutting 2026 adjusted EBITDA guidance roughly 11% to $775M-$825M at Q2 2026 results, after admitting customers had built excess Opteon inventory and the channel was oversupplied heading into 2026.","key_figures":{"customDimensions":{"stock_drop_date":"August 5, 2026","stock_drop_percent":"18.63%","stock_drop_price_to":14.59,"stock_drop_price_from":17.93,"ebitda_guidance_cut_to":"$775M – $825M","lead_plaintiff_deadline":"December 7, 2026","q2_net_sales_change_yoy":"approximately -1%","ebitda_guidance_cut_from":"$800M – $900M"}},"named_entities":{"people":[{"name":"Adam McCall","role":"law firm contact"}],"products":["Opteon"],"companies":[{"name":"The Chemours Company","ticker":"CC","relationship":"target of class action"},{"name":"Bleichmar Fonti & Auld LLP","relationship":"plaintiff law firm"}],"dollarAmounts":[{"amount":"$800M – $900M","context":"original 2026 adjusted EBITDA guidance"},{"amount":"$775M – $825M","context":"cut 2026 adjusted EBITDA guidance"},{"amount":"$3.34 per share","context":"August 5, 2026 stock drop"},{"amount":"$17.93 per share","context":"closing price August 4, 2026"},{"amount":"$14.59 per share","context":"closing price August 5, 2026"}]},"model_name":"glm-5.3-flashx","prompt_hash":"sha256:5c812bd9e28b810d","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-10-27T09:46:10.380Z","global_importance":20,"audience_relevance":25,"importance_components":{"tickerTier":"mid-cap","eventGravity":"law-firm-solicitation","issuerAuthored":false,"underlyingSeverity":"large stock drop and guidance cut already public"}},"durationMs":null,"modelName":"glm-5.3-flashx"}}